



HERBERT SMITH FREEHILLS ADVISES FIRST H-SHARE ISSUER TO LIST UNDER HONG KONG STOCK EXCHANGE'S BIOTECH RULES/ 首創香港交易所生物醫藥 3+H上市規則

24 December 2018 | Asia
News

Leading global law firm Herbert Smith Freehills has advised the banking syndicate involved in China drug developer Shanghai Junshi Biosciences Co., Ltd.'s US\$394 million IPO and listing on the Hong Kong Stock Exchange. 首創香港交易所生物醫藥3.94

CICC was the sole sponsor for the transaction, with Citibank, Credit Suisse, Fosun Hani, China International Securities and Caitong International Securities acting as joint bookrunners and lead managers.

Junshi is the first H-share issuer and first National Equities Exchange and Quotations-listed firm to take advantage of the exchange's newly relaxed listing rules for early-stage biotech companies.

"Investing in early-stage companies of any kind on any exchange requires a long-term view and a field of sophisticated investors," said partner Jason Sung, who led the team advising Junshi.

"In an already record year for the Hong Kong IPO market, the biotech rules have attracted a new pipeline of listings as well as investment from the world's leading biotech and pharma funds."

